Table 3.

Grades of hypertension resulting as a side effect of cancer therapy per the NCI Common Terminology Criteria for Adverse Events (CTCAE) [39]

Grade of Hypertension	Severity
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated	Systolic BP 120–139 mmHg or diastolic BP 80–89 mmHg
Grade 2 Moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL	Systolic BP 140–159 mmHg or diastolic BP 90–99 mmHg; Recurrent or persistent elevation (>  24 h); Symptomatic increase by > 20 mmHg (diastolic) or to > 140/90 mmHg if previously WNL; Monotherapy is indicated
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL	Systolic BP > 160 mmHg or diastolic BP > 100 mmHg; Medical intervention is indicated; Requires more intensive therapy than previously used or more than one drug
Grade 4 Life-threatening consequences; urgent intervention indicated	Life-threatening consequences (malignant hypertension, transient or permanent neurological deficit, hypertensive crisis); Urgent intervention is indicated
Grade 5 Death related to AE	Death

Adapted from Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Published Nov,2017